Opens in a new tab

Demis Hassabis, The Nobel Laureate With Cypriot Roots, Raises $5 Billion For AI Drug Discovery

by News Editor

Isomorphic Labs, the London-based artificial intelligence company developing new medicines, has raised $5 billion in Series C funding as it prepares to advance its first AI-designed drug candidates towards clinical trials.

The investment was co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz (a16z), Alphabet and several other new and existing investors.

The company is led by Sir Demis Hassabis, the Nobel Prize-winning scientist and co-founder of Google DeepMind, whose father is Greek-Cypriot, with family roots in Famagusta.

The latest funding milestone comes as Isomorphic Labs seeks to apply advances in artificial intelligence to one of medicine’s most difficult challenges: designing new drugs more accurately and efficiently.

From AI Models To Potential Medicines

Founded in 2021, Isomorphic Labs develops AI systems that model molecular interactions and help researchers identify promising drug candidates.

At the centre of its research is IsoDDE, a proprietary AI drug design engine combining simulation models that work across different diseases and types of medicines.

The technology allows scientists to explore potential molecular structures, predict their properties and refine designs before moving into experimental development.

According to the company, its models are producing encouraging preclinical results across internal programmes focused on cancer and immune-related diseases, as well as research conducted with pharmaceutical partners.

The new funding will support further development of IsoDDE, expansion of the company’s drug candidate pipeline and the infrastructure needed to progress potential treatments towards clinical testing.

“When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level,” said Hassabis.

He explained that the latest investment would allow the company to expand its biological models, improve its understanding of disease and move its first therapeutic programmes closer to clinical trials.

A $5 Billion Investment In AI-Driven Drug Discovery

The Series C round was co-led by Greenoaks and Sequoia Capital, alongside Andreessen Horowitz and other new investors.

Alphabet also made a significant additional investment, while existing backers Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund participated in the round.

The announcement follows a $2.1 billion Series B financing round in May 2026, reflecting continued investor interest in the company’s approach to AI-led medicine development.

Beyond advancing its own drug candidates, Isomorphic Labs plans to expand its partnerships with organisations working in disease biology and develop the infrastructure needed to support AI-driven drug research at a larger scale.

The company is also investing in translational and clinical development capabilities, which connect discoveries made during laboratory research with the testing and development of potential treatments for patients.

Max Jaderberg, President of Isomorphic Labs, said the company’s AI models were contributing to improvements in the molecular properties of potential new medicines, including in areas where conventional research has encountered longstanding difficulties.

Isomorphic Labs, headquartered in London with offices in Cambridge, Massachusetts, and Lausanne, Switzerland, is seeking to turn advances in AI-based molecular modelling into potential treatments.

Its latest investment provides substantial additional capital for that effort, although the effectiveness and safety of its drug candidates will still need to be established through clinical development.

Back

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter